FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387143075> ?p ?o ?g. }

• W4387143075 abstract "Primary immune thrombocytopenia is an autoimmune disorder mediated partly by platelet autoantibodies, resulting in thrombocytopenia, bleeding, and constitutional symptoms. Efgartigimod, a first-in-class novel human IgG1 Fc fragment, binds the neonatal Fc receptor with high affinity and thus reduces serum IgG concentrations, including autoantibodies. The objective of this study was to evaluate the efficacy and safety of efgartigimod in adults with persistent and chronic primary immune thrombocytopenia.This phase 3, multicentre, randomised, double-blinded, placebo-controlled, 24-week study evaluated the efficacy and safety of intravenous efgartigimod in adults aged 18 years or older with chronic or persistent primary immune thrombocytopenia who had an average platelet count of less than 30 000, had responded to at least one previous immune thrombocytopenia therapy, and were on a concurrent therapy at baseline or had received at least a second previous immune thrombocytopenia therapy. The study took place in 71 participating sites from Asia, Europe, and North America. Patients were randomly assigned 2:1 to receive either efgartigimod (10 mg/kg) or placebo intravenously for the first 4 weeks, after which the dosing schedule could be altered to once per week or every other week depending on the patients' platelet count. The primary endpoint, evaluated in the chronic population, was sustained platelet count response (≥50 × 109 for at least 4 of the last 6 weeks). This study is registered with ClinicalTrials.gov (NCT04188379) and is completed.A total of 205 patients were screened from Dec 9, 2019, to Feb 3, 2022, and 131 (86 in the efgartigimod group; 45 in the placebo group) were randomly assigned. These patients represented a population with long-term disease who had a mean time since diagnosis of 10·6 years and 67% (88/131) of whom had received at least three previous immune thrombocytopenia treatments. 22% (17/78) of patients with chronic immune thrombocytopenia receiving efgartigimod reached the primary endpoint compared with 5% (2/40) of those receiving placebo (p=0·032; adjusted difference in response, 16% [95% CI 2·6-26·4]). The median number of weeks of disease control in patients with chronic immune thrombocytopenia was 2·0 (IQR 0·0-11·0) for efgartigimod versus 0·0 (0·0-1·0) for placebo (p=0·0009). Efgartigimod was well tolerated; most adverse events were mild to moderate in severity. The most common adverse events of interest in both groups were headache (16% in efgartigimod and 13% in placebo), haematuria (16% in efgartigimod and 16% in placebo), and petechiae (15% in efgartigimod and 27% in placebo).Efgartigimod significantly increased sustained platelet count responses compared with placebo in patients with chronic immune thrombocytopenia, including those who had received multiple previous immune thrombocytopenia therapies. Upon completion of the ADVANCE IV study, patients could enroll in the ongoing open-label extension. Subcutaneous efgartigimod is currently being evaluated in patients with immune thrombocytopenia in the ADVANCE SC+ trial.argenx." @default.
• W4387143075 created "2023-09-29" @default.
• W4387143075 creator A5000522683 @default.
• W4387143075 creator A5002237220 @default.
• W4387143075 creator A5002284882 @default.
• W4387143075 creator A5004041185 @default.
• W4387143075 creator A5005053658 @default.
• W4387143075 creator A5006863054 @default.
• W4387143075 creator A5011059993 @default.
• W4387143075 creator A5011951771 @default.
• W4387143075 creator A5012342629 @default.
• W4387143075 creator A5012421001 @default.
• W4387143075 creator A5013112899 @default.
• W4387143075 creator A5013529815 @default.
• W4387143075 creator A5014334441 @default.
• W4387143075 creator A5016310424 @default.
• W4387143075 creator A5018367645 @default.
• W4387143075 creator A5018463325 @default.
• W4387143075 creator A5019004334 @default.
• W4387143075 creator A5020780800 @default.
• W4387143075 creator A5021562807 @default.
• W4387143075 creator A5022059136 @default.
• W4387143075 creator A5022676969 @default.
• W4387143075 creator A5023162972 @default.
• W4387143075 creator A5023907058 @default.
• W4387143075 creator A5024385941 @default.
• W4387143075 creator A5024573108 @default.
• W4387143075 creator A5027094790 @default.
• W4387143075 creator A5027588079 @default.
• W4387143075 creator A5029759839 @default.
• W4387143075 creator A5031024904 @default.
• W4387143075 creator A5033274539 @default.
• W4387143075 creator A5033913294 @default.
• W4387143075 creator A5033919093 @default.
• W4387143075 creator A5034882455 @default.
• W4387143075 creator A5034997188 @default.
• W4387143075 creator A5036366385 @default.
• W4387143075 creator A5037694593 @default.
• W4387143075 creator A5037716962 @default.
• W4387143075 creator A5041099068 @default.
• W4387143075 creator A5042699620 @default.
• W4387143075 creator A5043888124 @default.
• W4387143075 creator A5045917230 @default.
• W4387143075 creator A5049882856 @default.
• W4387143075 creator A5051231544 @default.
• W4387143075 creator A5051544503 @default.
• W4387143075 creator A5053464214 @default.
• W4387143075 creator A5053638396 @default.
• W4387143075 creator A5054654885 @default.
• W4387143075 creator A5056016951 @default.
• W4387143075 creator A5056136082 @default.
• W4387143075 creator A5056713408 @default.
• W4387143075 creator A5059870229 @default.
• W4387143075 creator A5061204994 @default.
• W4387143075 creator A5062322697 @default.
• W4387143075 creator A5062688748 @default.
• W4387143075 creator A5064189547 @default.
• W4387143075 creator A5065169573 @default.
• W4387143075 creator A5065276140 @default.
• W4387143075 creator A5065812269 @default.
• W4387143075 creator A5066258828 @default.
• W4387143075 creator A5066408727 @default.
• W4387143075 creator A5066738096 @default.
• W4387143075 creator A5068017566 @default.
• W4387143075 creator A5070399571 @default.
• W4387143075 creator A5070704251 @default.
• W4387143075 creator A5072344712 @default.
• W4387143075 creator A5074445253 @default.
• W4387143075 creator A5075492878 @default.
• W4387143075 creator A5075559564 @default.
• W4387143075 creator A5077408807 @default.
• W4387143075 creator A5080599868 @default.
• W4387143075 creator A5083391362 @default.
• W4387143075 creator A5084274462 @default.
• W4387143075 creator A5085298680 @default.
• W4387143075 creator A5085901299 @default.
• W4387143075 creator A5086480574 @default.
• W4387143075 creator A5086507996 @default.
• W4387143075 creator A5087414641 @default.
• W4387143075 creator A5088360970 @default.
• W4387143075 creator A5090305313 @default.
• W4387143075 creator A5091539057 @default.
• W4387143075 creator A5032611927 @default.
• W4387143075 date "2023-09-01" @default.
• W4387143075 modified "2023-10-16" @default.
• W4387143075 title "Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial" @default.
• W4387143075 cites W1847195880 @default.
• W4387143075 cites W1974541132 @default.
• W4387143075 cites W1984073642 @default.
• W4387143075 cites W2055407968 @default.
• W4387143075 cites W2061641422 @default.
• W4387143075 cites W2071843728 @default.
• W4387143075 cites W2126825171 @default.
• W4387143075 cites W2132094154 @default.
• W4387143075 cites W2136971471 @default.
• W4387143075 cites W2150724291 @default.
• W4387143075 cites W2156817733 @default.
• W4387143075 cites W2167805334 @default.
• W4387143075 cites W2799711263 @default.
• W4387143075 cites W2883123810 @default.

• next